Orion published Interim Report for January-September 2019 on Wednesday 23 October 2019.
|12/18/2019||33,944 Orion Corporation A shares converted into B shares|
|11/28/2019||Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%|
|11/28/2019||192,172 Orion Corporation A shares converted into B shares|
|11/4/2019||125,000 Orion Corporation A shares converted into B shares|
|12/30/2019||Lotus to distribute Orion’s Stalevo® and Comtan® drugs in parts of Asia|
|12/9/2019||Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND|
|12/2/2019||Orion to present four posters on oral levosimendan in patients with ALS at the 30th International Symposium on ALS/MND|
|11/4/2019||Orion Research Foundation grants 902 000 euros for research in 2020|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.